Spatial transcriptomics and single-cell analyses reveal the role of the cisplatin-resistant gene panel in NSCLC progression and the tumor microenvironment, identifying LOXL2 as a potential therapeutic target
BACKGROUND: Non-small cell lung cancer (NSCLC) patients often develop resistance to platinum-based chemotherapy, especially cisplatin, leading to treatment failure. This study aimed to identify high-score epithelial cells in tumors within the cisplatin-resistant gene panel (CRGP) …
Read PDF